Abstract Axillary lymph node status is the most powerful prognostic indicator in patients with breast cancer. FDG-PET has been suggested as a non-invasive method of staging the axilla. The aim of this study was to review and aggregate all studies that measured the performance of FDG-PET in patients with breast cancer, using surgically obtained axillary histology as a reference, in a meta-analysis. A systematic review of the literature was performed and data extracted from all eligible studies. These were then analysed using meta-analysis software and summary receiver operating characteristic (SROC) curves were plotted for the aggregate data. The data was then tested to determine which parameters impacted on the sensitivity and specificity of the studies. Sensitivities ranging from 20 to 100% and specificities ranging from 65 to 100% have been reported. An aggregated ROC analysis found an area under the curve of 0.95 (95% CI 0.91-0.97) and a Q* value of 0.89 (95% CI 0.85-0.92) in a total of 25 studies involving 2,460 patients. The AUC and Q* values indicated little difference between the compared study characteristics. The performance of the technique currently remains below, which is required to replace assessment of axillary node status by surgical biopsy and histological assessment. However, sensitivity and specificity are high and FDG-PET may have a role to play under particular circumstances. Moreover, the additional benefit of an assessment of distal metastatic spread provided by FDG-PET requires further investigation.
Introduction
Although a number of prognostic indicators have been identified in patients with breast cancer, the most powerful of all in terms of identifying patients with a poorer prognosis remains histological assessment of axillary lymph node involvement with tumour [1, 2] . At the present time, in all patients with invasive breast cancer, histological assessment of the patient's axillary node(s) is recommended by surgically removing a lymph node(s) by one of three standard procedures; sentinel lymph node biopsy (SNB), axillary sample and axillary clearance. These procedures require a period of hospital admission, a surgical operation with its attendant financial costs and post-operative morbidity (physical and psychological) [3] . Recent interest has focused on SNB as a method to stage the axilla. This technique has resulted in a significant reduction in morbidity compared with axillary lymph node dissection (ALND) and clearance [4] . It is unsuccessful in 3-6% of patients and has a false negative rate of 2.1-2.7% when compared to axillary node dissection and clearance [5, 6] . The nature of SNB means that it has no false positives and consequently no patient is erroneously upstaged in terms of their tumour.
Surgical staging provides essential information in the management of breast cancer, but the disadvantages make it imperfect. A better staging tool would be one with a superior or equivalent diagnostic performance without the disadvantages of surgery. One technique that has attracted considerable interest as a possible non-invasive method of staging the axilla has been FDG-PET. Since the initial studies, reported some 20 years ago, further studies have reported a range of sensitivity ranging from 20 to 100% and specificity ranging from 65 to 100% . At its best FDG-PET appears good enough to replace surgery in some situations, however, this predominately is not the case. To our knowledge, no study has carried out a systematic review and meta-analysis of FDG-PET in the staging of the axilla. The aim of our study is to review the literature, aggregate the results and to compare the acquisition protocols in order to identify best practice.
Although our focus is on PET it would be imprudent to look at its performance in isolation from other imaging modalities used in staging. It is common clinical practice in patients with breast cancer to carry out ultrasound of the axilla together with fine needle aspiration cytology of any suspicious axillary nodes that are identified (or palpable) prior to patients undergoing SNB [10] . Similarly MRI [11, 32] , CT [33, 34] , mammography [7, 11] and other non-PET radionuclides (MIBI) [25] have all been suggested as useful in the staging of the axilla. It would not be the aim to perform a complete review of all modalities at this stage, since an extensive number of studies have not been carried out in all modalities. We aim, in this analysis, to review studies where there has been a direct comparison of other staging techniques with PET.
Aggregating findings from imaging studies with and without quantitation is not a simple process due to the lack of homogeneity. Summary receiver operating characteristics (SROC) analysis is a statistical technique that can be applied to meta-analysis of imaging tests. The technique overcomes the limitations associated with simple pooling of sensitivities and specificities of published studies [35] . In this study, we apply this approach to summarise published data describing performance using the area under the ROC curve (AUC) and the point where the sensitivity equals the specificity on the ROC curve (Q*), which are common figures of merit for evaluating performance.
Method
Data sources consisted of Ovid MEDLINE Ò 1950 to June Week 2 2009, for which we used the exploded MeSH heading 'breast neoplasm' combined with the exploded MeSHs 'positron emission tomography' or 'Tomography, emission-computed' or 'Fluorodeoxyglucose F18' (1,067 articles identified). These titles were searched for the following keywords: axilla, staging, nodes, nodal (375 articles identified). Abstracts were then reviewed by one author (R.P.) and all potentially relevant studies retrieved to assess eligibility for inclusion (45 studies). All potentially eligible studies were reviewed by R.P. and studies not meeting the eligibility criteria were excluded. Studies with questionable eligibility were reviewed by another author (R.S.) and a consensus reached. The eligibility criteria were as follows. We excluded: studies not in English, small studies (\20 patients), studies using gamma camera PET only, studies where the results were included in a follow-up study (i.e. we excluded pilot studies to avoid using data twice), studies that did not perform ALND or SNB and used follow-up or FNAC, etc. for gold standard. Where patients that did not have ALND or SNB could be extracted from the data, the study was included but only the data for the ALND or SNB patients used. Similarly, studies which contained patients with benign tumours were included, but the benign patient data was excluded from the analysis. We also excluded one potentially eligible study as the FP/TN results could not be extracted [36] . Twenty-five studies were found to satisfy these criteria.
The data extraction process was completed independently by two authors (R.P. and R.S.) discrepancies were settled by consensus. All discrepancies were settled this way and it was not necessary to use a third reviewer. TP, TN, FN and FP values were extracted from the data given. If TP, TN, FN and FP figures were not explicitly given, these were calculated from the available data, e.g. sensitivity, specificity, PPV and NPV. If a range of values was given (e.g. if a range of different SUV cut-offs were used), then the value reported as 'optimum' by the authors was used. If data from different readers was given then the combined result as reported by the authors was used. If the resolution was not reported in the article then previous articles from the same group quoting resolution were sought [37] . If this could not be found then resolution measurements from other groups using the same system, or articles reporting the performance of the system were used [38] [39] [40] . A qualitative study was defined as the one that used purely visual analysis to determine if a result was positive or negative. A quantitative study was defined as the one that used an SUV cut-off as the primary determination of positivity. A semi-quantitative study was defined as the one that used quantification of any kind, but interpreted it in conjunction with visual analysis.
All data available regarding the type of PET system, including whether it was PET/CT or stand-alone PET, its resolution, use of attenuation correction, time to imaging, administered activity, scanning position, and whether quantitative assessment was used, was collated either directly from the article or inferred based on the type of system used. Sensitivities, specificities and diagnostic odds ratios (DOR) for each study were calculated. The DOR expresses how much greater the odds of having the disease are for the people with a positive test result than for the people with a negative test result. It is a single measure of diagnostic test performance that combines both likelihood ratios [41] .
The data was entered into meta-analysis software [41] and analysis performed using a weighted least squares method, weighting by study size and using a restricted maximum likelihood technique. The results of this analysis were used to plot SROC curves. The AUC were found using the trapezoidal method as described previously [42] . The Q* value represents the point on the SROC curve, where the sensitivity equals the specificity. AUC and Q* are figures of merit used to describe ROC curves.
Results
A summary of the studies that satisfied the inclusion criteria detailed above are shown in Table 1 , giving details of the key characteristics of the study. By definition all studies had staging the axilla as part of their aims. This was either stated as the primary aim of the study or as a parallel aims along with the assessment of the primary and comparison with other modalities. Inclusion and exclusion criteria for the studies were varied. In general, previous treatment/ surgery was an exclusion criterion. Some studies define the primary tumour by size and/or type and where stated a significant proportion of the studies excluded patients with confirmed disease spread. The age ranges of the samples were similar; the studies were predominately prospective and involved consecutive recruitment. All studies performed ALND in a proportion of the patients and most PET data was analysed independently of other information by more than one reader. The predominate reason given by the authors for the false negative results was the presence of micro-metastases.
A summary of the technical variables and performance is shown in Table 2 . The later studies, as expected, used PET/CT. The median time to imaging was 1 h, the median activity used was 370 MBq and the majority of studies imaged in the supine position. Analysis of the data was evenly split between quantitative and qualitative approaches and Filtered Back Projection was the predominate method of reconstruction. Table 2 shows the DOR for each study demonstrating the range of performance levels achieved with this technique.
The combined patient population was 2,460 with 703 true positives, 1,288 true negatives, 339 false negatives and 130 false positives. The AUC of the SROC curve (AUC) was 0.95 (95% CI 0.91-0.97) and the Q* value was 0.89 (95% CI 0.85-0.92). The AUC is a figure of merit for ROC curves, 1 represents perfect performance and 0.5 represents random performance. A SROC curve weighted by the number of patients in the study is shown in Fig. 1. The data set was then analysed by splitting the sample, where possible, by key study characteristics and comparing them using the SROC software. The sample was split into subsets with at least four studies and containing at least 200 patients. The study characteristics compared were: (i) resolution \5 mm compared to resolution C5 mm (FWHM); (ii) studies using attenuation correction compared to studies without attenuation correction; (iii) studies using a prone imaging position compared to studies using a supine position; (iv) studies using only visual interpretation of the image compared to studies using a quantitative approach; (v) studies using PET/CT systems compared to studies that used PET only and (vi) studies that included SNB compared to studies that used ALND only. The results are given in Table 3 . The AUC values indicated little difference between the compared characteristics. The Q* value showed significant overlap between the 95% CI in each case. There is a trend towards the studies with the poorer resolution having a better AUC and Q*. The same is true for studies that use CT and studies that included a SNB biopsy. This is predominantly the same group of studies, i.e. studies that had CT also had a better resolution and used SNB.
Those studies that compared different imaging techniques and clinical assessment with PET (/CT) using pathology as the gold standard are shown in Table 4 . Data for MRI, mammography, MIBI and gamma camera PET is sparse. The general indication is that PET is superior to mammography, MIBI and gamma camera PET and is similar to MRI. Clinical comparisons and ultrasound comparisons allow a limited statistical comparison. The summary ROC curve AUC and Q* for the clinical assessment was 0.78 (CI 0.38-0.96) and 0.83 (CI 0.73-0.90), respectively, for eight studies using 755 patients. Using the same sub group of studies and the PET performances an AUC of 0.94 (CI 0.86, 0.98) and a Q* of 0.88 (CI 0.80, 0.94) were calculated. Similarly ultrasound produced an AUC of 0.90 (CI 0.79, 0.96) and a Q* of 0.83 (CI 0.73, 0.90) using four studies and 348 patients. Using the same sub group of studies and the PET performances an AUC of 0.93 (CI 0.72, 0.98) and a Q* of 0.87 (CI 0.67, 0.95) were calculated. In each case, the performance of the techniques was lower than the complete PET sample performance and the sub samples for each comparison, although, there is overlap between the CI for each estimate.
Discussion
We have calculated the aggregated performance of FDG-PET (/CT) by examining 25 studies which involved a total of 2,460 patients. A Q* (sensitivity = specificity) of 0.89 (95% CI 0.85-0.92) and an AUC of 0.95 (95% CI 0.91-0.97) were calculated. In radiological terms this would normally be considered a 'good' performance. In this clinical setting, however, the performance is not sufficiently good enough to replace surgical biopsy of the axillary lymph node(s) and histological evaluation to determine the presence or absence of metastatic disease in axillary lymph nodes. It is clear from our results that FDG-PET (/CT) is not the panacea for staging breast cancer and in particular the axilla. It is difficult to assess study quality although certain features such as multiple readers, images independently read, consecutive recruitment, a prospective design and ALND as the gold standard would be qualities of merit. 18 (72%) of the studies in this analysis had four or more of these features. The AUC for these 18 studies was 0.95 (95% CI 0.91-0.97) and the Q* was 0.90 (95% CI 0.85-0.93). Three studies (12%) had only one of these features, although in one of these cases the appropriate information was not given in the manuscript. Given these attributes the sample of studies was of acceptable quality. The distribution of study data points in our SROC curve (Fig. 1 ) was relatively even along our fitted ROC line indicating that a range of confidence thresholds were sampled and that the ROC line was a reasonable estimate of the techniques performance for a range of confidences.
The reasons for this less than perfect performance are varied. Most studies report false negative results. The main reason given for these findings is the inability of PET, PET/ CT to detect small metastatic deposits (micro-metastases). It is interesting to note that this is more often the case in the later, more modern, studies and may be a result of better pathological detection. This would represent a shift in the gold standard rather than a shift in the performance of the technique. Authors have also postulated that primary tumour characteristics, such as avidity, are associated with the metastatic avidity [14, 19, 21, 24] . Therefore, a primary with a low avidity will result in difficult to detect nodal metastases. Similarly, authors have also identified larger patients as a cause for false negative results [18] . This is a common obstacle faced in nuclear medicine, where obese patients produce images of inferior quality. Future studies may well consider adjusting protocols when imaging such patients, such as extending acquisition time. One study, Schirrmeister et al. [23] , imaged a portion of patients after chemotherapy and concluded that imaging patients post therapy increased the number of false negatives. Similarly, studies also report false positives and have identified previous biopsy [15, 17] other tumours (e.g. non-Hodgkin lymphoma [20] ) and infective and inflammatory conditions (a rabies vaccination [29] , nodes affected by tuberculosis [14] and an acute infection of the contra lateral hand [43] ) as the origins of these false positives. Therefore, patients who had prior chemotherapy, previous biopsy, other Where the reference standard is ALND and SNB, ALND was performed regardless of SNB result, where it is ALND and/or SNB, ALND was not performed in patients with both SNB and PET negative results. 4. Suggested reasons for false negative results; micro-mets: studies indicated that PET is not sensitive enough to detect micro-metastases. Fewer nodes: studies suggested that if only one node was affected the sensitivity of PET to detect metastases was reduced. Smaller metastases: studies suggested that smaller metastases are more difficult to detect. Treatment: one study suggested an association between the use of neo-adjuvant chemotherapy and a reduced sensitivity. Position of the patient; one study suggested that patients positioned with arms by their sides made it difficult to differentiate level I axillary lymph nodes from breast tumours in the upper outer quadrant. Primary tumour characteristics: several studies found an association between the characteristics of the primary tumour such as tumour type and grade, SUV and avidity, and the sensitivity. Larger patients: some studies found that larger patients were associated with a decrease in sensitivity tumours or infective and inflammatory conditions would not be suitable for this approach. Taken collectively, the reasons given for the false negatives identify a limit to the sensitivity of PET (/CT). The limited number of comparison studies between PET (/CT) and other modalities, shown in Table 4 , indicated that it has a similar performance to ultrasound and MRI and probably better that mammography, gamma camera PET and radionuclide imaging with MIBI. Given the expense of PET (/CT) and radiation dose these findings would indicate the ultrasound would be the modality of choice. However, no single modality provides complete characterisation of the axilla in breast cancer and complementary information is gained for both structural and metabolic imaging. The current management challenge is to devise a management protocol that optimises all available modalities on an individual patient basis.
One possible management protocol would be to perform an FDG-PET (/CT) study prior to surgery if no other diagnostic test, such as ultrasound, has identified the axilla as positive for metastatic involvement. PET would then identify a group of patients not requiring SNB. These patients could proceed immediately to a more appropriate management of their axilla, i.e. axillary clearance without the need for the intervening step of SNB. This potential tool should also be seen in the context of the additional information that modern PET/CT provides with respect to the presence or absence of additional primary sites, detectable distant metastatic disease and internal mammary lymph gland involvement by tumour. Eight of the studies in this analysis included patients in whom distant disease was detected by PET, either in the internal mammary chain, distant metastases or synchronous tumours. In most cases, this would not have been detected by conventional staging procedures. One study, Fuster et al. [9] , found that PET led to a change in the initial staging in 42% of patients. These advantages have been recently described in a study by Heusner et al. [36] who has suggested that whole body PET/CT can provide a 'one stop' staging examination for patients with breast cancer. If used in this way then the emphasis when staging the axilla would be on a low false positive rate, which would limit the number of unnecessary axillary clearances.
None of the imaging protocol characteristic comparisons indicated a superiority of one protocol aspect over another. 
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Sensitivity Fig. 1 The SROC for all studies included in the meta-analysis This was surprising as it could be expected at modern PET/ CT systems would be superior over PET only systems due to the additional anatomical information gained. This was not the case. The trend was in the opposite direction with the older systems having a superior AUC and Q*. This may have been brought about by a shift in the gold standard described above. The results suggest that minor imaging protocol variations do not have a significant impact on performance. However, the literature reviewed suggests that FDG-PET has potential as a complementary test. To truly assess the potential of this technique studies must move beyond a relatively simple assessment of accuracy in isolation of other relevant clinical information. Future studies should investigate the complementary role of FDG-PET (/CT) in breast cancer, combined with other modalities, in terms of its cost/benefit and impact on the 'patient journey'. 
